-

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person:

  • Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside Chat on Monday, November 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts
  • Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 3:20 p.m. ET in New York City, New York

A live webcast of both presentations can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Contacts

Media
Amylyx Media Team
+1 (857) 320-6244
amylyxmediateam@amylyx.com

Investors
Courtney O’Leary
Amylyx Pharmaceuticals, Inc.
+1 (978) 621-7347
Investors@amylyx.com

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Release Summary
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Release Versions
$Cashtags

Contacts

Media
Amylyx Media Team
+1 (857) 320-6244
amylyxmediateam@amylyx.com

Investors
Courtney O’Leary
Amylyx Pharmaceuticals, Inc.
+1 (978) 621-7347
Investors@amylyx.com

Social Media Profiles
More News From Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026...

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting...

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum...
Back to Newsroom